Drugs / octreotide pamoate

Trials 1 · a red edge is where a trial was stopped

201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01469338 Jul 2012 → Oct 2014 diarrheal disease, hormone-resistant prostate carcinoma University of Southern California Terminated No outcome recorded

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as octreotide pamoate ClinicalTrials.gov intervention name — accepted as the source's own label NCT01469338
Known as Bynfezia pen ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Known as Octreotida ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Known as Octreotide acetate (preservative free) ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Known as Octreotide embonate ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Known as Sandostatin lar ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Known as SMS 201-995 PA ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Known as SMS PA ChEMBL registry synonym — accepted as the source's own label CHEMBL1680
Modality Protein / enzyme biologic CHEMBL1680
Route Intramuscular “octreotide pamoate given as intramuscular (IM) injection” NCT01469338